Manufacturer
Takeda GmbH
Contents
Pantoprazole Na
Indication
Short term use for symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion: Duodenal ulcer; Gastric ulcer; Moderate and severe reflux esophagitis; Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.
Instruction
Inj Gastric & duodenal ulcer, moderate & severe reflux oesophagitis 40 mg IV daily if oral therapy is inappropriate. Zollinger-Ellison syndrome & other pathological hypersecretory conditions 80 mg IV daily, may be titrated up or down as needed.
Drug interaction
Interfered absorption of pH-dependent drugs. Reduced bioavailability of atazanavir, nelfinavir. Elevated & prolonged serum levels of methotrexate &/or its metabolite. Increased whole blood levels of tacrolimus. Increased systemic exposure by fluvoxamine. Increased INR & prothrombin time w/ coumarin anticoagulants (eg, phenprocoumon or warfarin).
Malaysia
